These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography. Bando R; Otsuka H; Otani T; Matsuda N; Azane S; Kunikane Y; Otomi Y; Sako W; Izumi Y; Harada M Ann Nucl Med; 2021 Apr; 35(4):504-513. PubMed ID: 33630226 [TBL] [Abstract][Full Text] [Related]
46. Modeling considerations for in vivo quantification of the dopamine transporter using [(11)C]PE2I and positron emission tomography. DeLorenzo C; Kumar JS; Zanderigo F; Mann JJ; Parsey RV J Cereb Blood Flow Metab; 2009 Jul; 29(7):1332-45. PubMed ID: 19458606 [TBL] [Abstract][Full Text] [Related]
47. Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. Kim JS; Cho H; Choi JY; Lee SH; Ryu YH; Lyoo CH; Lee MS PLoS One; 2015; 10(7):e0132585. PubMed ID: 26147749 [TBL] [Abstract][Full Text] [Related]
48. [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Saba W; Valette H; Schöllhorn-Peyronneau MA; Coulon C; Ottaviani M; Chalon S; Dolle F; Emond P; Halldin C; Helfenbein J; Madelmont JC; Deloye JB; Guilloteau D; Bottlaender M Synapse; 2007 Jan; 61(1):17-23. PubMed ID: 17068778 [TBL] [Abstract][Full Text] [Related]
49. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779 [TBL] [Abstract][Full Text] [Related]
50. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650 [TBL] [Abstract][Full Text] [Related]
51. Reliability and validity of visual analysis of [ 18 F]FE-PE2I PET/CT in early Parkinsonian disease. Af Bjerkén S; Axelsson J; Larsson A; Flygare C; Remes J; Strandberg S; Eriksson L; Bäckström D; Jakobson Mo S Nucl Med Commun; 2023 May; 44(5):397-406. PubMed ID: 36862448 [TBL] [Abstract][Full Text] [Related]
52. Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. Varrone A; Stepanov V; Nakao R; Tóth M; Gulyás B; Emond P; Deloye JB; Vercouillie J; Stabin MG; Jonsson C; Guilloteau D; Halldin C J Nucl Med; 2011 Aug; 52(8):1313-21. PubMed ID: 21764797 [TBL] [Abstract][Full Text] [Related]
53. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients. Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330 [TBL] [Abstract][Full Text] [Related]
54. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. Pinborg LH; Ziebell M; Frøkjaer VG; de Nijs R; Svarer C; Haugbøl S; Yndgaard S; Knudsen GM J Nucl Med; 2005 Jul; 46(7):1119-27. PubMed ID: 16000280 [TBL] [Abstract][Full Text] [Related]
55. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. Chalon S; Hall H; Saba W; Garreau L; Dollé F; Halldin C; Emond P; Bottlaender M; Deloye JB; Helfenbein J; Madelmont JC; Bodard S; Mincheva Z; Besnard JC; Guilloteau D J Pharmacol Exp Ther; 2006 Apr; 317(1):147-52. PubMed ID: 16339913 [TBL] [Abstract][Full Text] [Related]
56. Subanesthetic S-ketamine does not acutely alter striatal dopamine transporter binding in healthy Sprague Dawley female rats. Bærentzen SL; Thomsen JB; Thomsen MB; Jakobsen S; Simonsen MT; Wegener G; Brooks DJ; Landau AM Synapse; 2024 Jul; 78(4):e22294. PubMed ID: 38813759 [TBL] [Abstract][Full Text] [Related]
57. [18F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease. Juri C; Kramer V; Riss PJ; Soza-Ried C; Haeger A; Pruzzo R; Rösch F; Amaral H; Chana-Cuevas P Clin Nucl Med; 2021 Feb; 46(2):119-124. PubMed ID: 33323728 [TBL] [Abstract][Full Text] [Related]
58. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103 [TBL] [Abstract][Full Text] [Related]
59. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography. Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314 [TBL] [Abstract][Full Text] [Related]
60. Electroconvulsive therapy decreases striatal dopamine transporter binding in patients with depression: A positron emission tomography study with [ Masuoka T; Tateno A; Sakayori T; Tiger M; Kim W; Moriya H; Ueda S; Arakawa R; Okubo Y Psychiatry Res Neuroimaging; 2020 Jul; 301():111086. PubMed ID: 32464340 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]